Your browser doesn't support javascript.
loading
Primary lateral sclerosis (PLS) functional rating scale: PLS-specific clinimetric scale.
Mitsumoto, Hiroshi; Chiuzan, Codruta; Gilmore, Madison; Zhang, Yuan; Simmons, Zachary; Paganoni, Sabrina; Kisanuki, Yasushi Y; Zinman, Lorne; Jawdat, Omar; Sorenson, Eric; Floeter, Mary Kay; Pioro, Erik P; Fernandes Filho, J Americo M; Heitzman, Daragh; Fournier, Christina Nicole; Oskarsson, Bjorn; Heiman-Patterson, Terry; Maragakis, Nicholas; Joyce, Nanette; Hayat, Ghazala; Nations, Sharon; Scelsa, Stephen; Walk, David; Elman, Lauren; Hupf, Jonathan; McHale, Brittany.
Afiliación
  • Mitsumoto H; Department of Neurology, Eleanor and Lou Gehrig ALS Center, Columbia University Irvine Medical Center, New York, New York.
  • Chiuzan C; Department of Biostatistics, Mailman School of Medicine, Columbia University, New York, New York.
  • Gilmore M; Department of Neurology, Eleanor and Lou Gehrig ALS Center, Columbia University Irvine Medical Center, New York, New York.
  • Zhang Y; Department of Biostatistics, Mailman School of Medicine, Columbia University, New York, New York.
  • Simmons Z; Department of Neurology, Pennsylvania State University, Hershey, Pennsylvania.
  • Paganoni S; Sean M. Healey & AMG Center for ALS, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
  • Kisanuki YY; Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts.
  • Zinman L; Department of Neurology, The Ohio State University, Columbus, Ohio.
  • Jawdat O; Department of Neurology, University of Toronto, Sunnybrook Hospital, Toronto, Ontario, Canada.
  • Sorenson E; Department of Neurology, University of Kansas, Kansas City, Kansas.
  • Floeter MK; Department of Neurology, Mayo Clinic, Minnesota, Rochester, Minnesota.
  • Pioro EP; Clinical Unit, National Institute of Neurological Diseases and Stroke, Bethesda, Maryland.
  • Fernandes Filho JAM; Department of Neurology, Cleveland Clinic, Cleveland, Ohio.
  • Heitzman D; Department of Neurology, University of Nebraska, Omaha, Nebraska.
  • Fournier CN; Texas Neurology, Dallas, Texas.
  • Oskarsson B; Department of Neurology, Emory University and Atlanta VA Medical Center, Atlanta, Georgia.
  • Heiman-Patterson T; Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, Florida.
  • Maragakis N; Department of Neurology, Temple University, Philadelphia, Pennsylvania.
  • Joyce N; Department of Neurology, Johns Hopkins University, Baltimore, Maryland.
  • Hayat G; Department of Neurology University of California Davis, Davis, California.
  • Nations S; Department of Neurology, St Louis University, St Louis, Missouri.
  • Scelsa S; Department of Neurology, University of Texas Southwestern, Dallas, Texas.
  • Walk D; Department of Neurology, Mount Sinai/Beth Israel Hospital, New York, New York.
  • Elman L; Department of Neurology, University of Minnesota, Minneapolis, Minnesota.
  • Hupf J; Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania.
  • McHale B; Department of Neurology, Eleanor and Lou Gehrig ALS Center, Columbia University Irvine Medical Center, New York, New York.
Muscle Nerve ; 61(2): 163-172, 2020 02.
Article en En | MEDLINE | ID: mdl-31758557
ABSTRACT

INTRODUCTION:

Our research aim was to develop a novel clinimetric scale sensitive enough to detect disease progression in primary lateral sclerosis (PLS).

METHODS:

A prototype of the PLS Functional Rating Scale (PLSFRS) was generated. Seventy-seven participants with PLS were enrolled and evaluated at 21 sites that comprised the PLSFRS study group. Participants were assessed using the PLSFRS, Neuro-Quality of Life (QoL), Schwab-England Activities of Daily Living (ADL), and the Clinical Global Impression of Change scales. Participants completed telephone assessments at 12, 24, and 48 weeks after enrollment.

RESULTS:

The PLSFRS demonstrated internal consistency as well as intrarater, interrater, telephone test-retest reliability, and construct validity. Significant changes in disease progression were detected at 6 and 12 months; changes measured by the PLSFRS vs the ALSFRS-R were significantly higher.

DISCUSSION:

The PLSFRS is a valid tool to assess the natural history of PLS in a shorter study period.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de la Neurona Motora Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Muscle Nerve Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de la Neurona Motora Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Muscle Nerve Año: 2020 Tipo del documento: Article